JAHA: Relationship between D-D-djubo levels and all-cause death and adverse functional outcomes in patients with ischemic stroke or transient cerebral ischemic episodes

D-D-polymer as a blood clotting biomarker was associated with poor prognosis in stroke patients.
Recently, researchers in JAHA, an authoritative journal in the field of cardiovascular disease, looked at the relationship between baseline and 90-day D-D-Dpomer levels and increased total cause of death or insanity in patients with ischemic stroke or transient cerebral ischemic episodes.
researchers collected data from a third national stroke registry (CNSRIII) study that included 10,518 patients with ischemic stroke or transient ischemic episodes within seven days and 6,268 patients over 90 days.
to assess adverse function outcomes over a ≥ based on the improved Lankin Scale (≥3).
multivariate Cox regression or Logistic regression is used to evaluate the association between D-djust levels and all-cause death or adverse function prognostics.
D-djumer level at 90 days is lower than at baseline (1.4 μg/mL vs. 1.7 μg/mL;P-lt;0.001).
year follow-up period, the higher baseline D-D-djudome level was 1.77 with an all-cause death (adjusted risk ratio of HR; 95% CI was 1.25-2.52; P=0.001) and adverse functional outcomes (adjusted ratio of .OR) was 1.49; 95% CI is 1.23-1.80;
D-D-D-polymer levels at 90 days were also associated with poor prognosm.
addition, an increase in D-D-djurgy levels between baseline and 90 days was associated with all-cause death (corrected HR was 1.99; 95% CI was 1.12-3.53; P=0.019).
results showed that higher baseline and 90-day D-polymer levels were associated with adverse outcomes in patients with ischemic stroke or transient ischemic episodes.